PURPOSE: A series of six lung cancer cell lines of different cell origin (including small cell and mesothelioma) were characterized immunohistochemically and the role of a series of protein candidates previously implicated in drug resistance were investigated. METHODS: These include colony-forming and cell growth assays, immunohistochemistry, siRNA knockouts, real-time PCR and western blots. RESULTS: No correlation was found with AKT, HO-1, HO-2, GRP78, 14-3-3zeta and ERCC1 levels and cisplatin nor oxaliplatin cytotoxicity, but an association was observed with levels of the enzyme, dihydrodiol dehydrogenase (DDH); an enzyme previously implicated in the development of platinum resistance. The relationship appeared to hold true for those cell lines derived from lung epithelial primary tumors but not for the neuroendocrine/small-cell and mesothelioma cell lines. siRNA knockouts to DDH-1 and DDH-2 were prepared with the cell line exhibiting the greatest resistance to cisplatin (A549) resulting in marked decreases in the DDH isoforms as assessed by real-time PCR, western blot and enzymatic activity. The DDH-1 knockout was far more sensitive to cisplatin than the DDH-2 knockout. CONCLUSION: Thus, sensitivity to cisplatin appeared to be associated with DDH levels in epithelial lung cancer cell lines with the DDH-1 isoform producing the greatest effect. Results in keeping with transfection experiments with ovarian and other cell lines.
PURPOSE: A series of six lung cancer cell lines of different cell origin (including small cell and mesothelioma) were characterized immunohistochemically and the role of a series of protein candidates previously implicated in drug resistance were investigated. METHODS: These include colony-forming and cell growth assays, immunohistochemistry, siRNA knockouts, real-time PCR and western blots. RESULTS: No correlation was found with AKT, HO-1, HO-2, GRP78, 14-3-3zeta and ERCC1 levels and cisplatin nor oxaliplatincytotoxicity, but an association was observed with levels of the enzyme, dihydrodiol dehydrogenase (DDH); an enzyme previously implicated in the development of platinum resistance. The relationship appeared to hold true for those cell lines derived from lung epithelial primary tumors but not for the neuroendocrine/small-cell and mesothelioma cell lines. siRNA knockouts to DDH-1 and DDH-2 were prepared with the cell line exhibiting the greatest resistance to cisplatin (A549) resulting in marked decreases in the DDH isoforms as assessed by real-time PCR, western blot and enzymatic activity. The DDH-1 knockout was far more sensitive to cisplatin than the DDH-2 knockout. CONCLUSION: Thus, sensitivity to cisplatin appeared to be associated with DDH levels in epithelial lung cancer cell lines with the DDH-1 isoform producing the greatest effect. Results in keeping with transfection experiments with ovarian and other cell lines.
Authors: Z S Chen; M Mutoh; T Sumizawa; T Furukawa; M Haraguchi; A Tani; N Saijo; T Kondo; S Akiyama Journal: Exp Cell Res Date: 1998-05-01 Impact factor: 3.905
Authors: G Pelosi; F Fraggetta; F Pasini; P Maisonneuve; A Sonzogni; A Iannucci; A Terzi; E Bresaola; F Valduga; C Lupo; G Viale Journal: Am J Surg Pathol Date: 2001-03 Impact factor: 6.394
Authors: P M Fernandez; S O Tabbara; L K Jacobs; F C Manning; T N Tsangaris; A M Schwartz; K A Kennedy; S R Patierno Journal: Breast Cancer Res Treat Date: 2000-01 Impact factor: 4.872
Authors: Julian C Desmond; Joanne C Mountford; Mark T Drayson; Elizabeth A Walker; Martin Hewison; Jonathan P Ride; Quang T Luong; Rachel E Hayden; Elio F Vanin; Christopher M Bunce Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Amanda J Pickard; Fang Liu; Thomas F Bartenstein; Laura G Haines; Keith E Levine; Gregory L Kucera; Ulrich Bierbach Journal: Chemistry Date: 2014-10-10 Impact factor: 5.236